SCOPE Summit 2025: Samuel Salvaggio Discusses Crucial Partnerships for Trial Efficiency

ACT: What types of partnerships—whether with CROs, technology vendors, or patient advocacy groups—do you see as crucial for improving trial efficiency and success?

Salvaggio: From my point of view, we principally work with site investigators and patient representatives. At One2Treat, we give tools for sponsors to interact with patient representative groups and site investigators, so they can get feedback on the best way to assess their treatment efficacy. By doing that, we think that it gives more value to the treatment that is being assessed, because now you can really measure what truly matters to these stakeholders.

Full Interview Summary: One2Treat s attending SCOPE to explore innovations in clinical trial operations, with a strong focus on patient-centric trial design. They highlight the event’s diverse range of participants, including companies, vendors, startups, and sponsors, all contributing to discussions on trial advancements.

While decentralized trials, real-world data integration, and AI-driven protocols are major industry trends, the speaker is primarily interested in how patient voices can be effectively integrated into trial design. They note that while the FDA has recently issued guidance on patient inclusion, it lacks detailed implementation strategies. Conferences like SCOPE provide a platform to discuss concrete methods for incorporating patient perspectives into trial strategies.

Regarding partnerships, Salvaggio emphasizes the importance of collaboration with site investigators and patient representatives. These stakeholders play a crucial role in ensuring that trials are designed with patient needs and experiences in mind, ultimately improving trial success and patient engagement.